Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Park, Jongwhi [VerfasserIn]   i
 Turcan, S̨evin [VerfasserIn]   i
Titel:Epigenetic reprogramming for targeting IDH-mutant malignant gliomas
Verf.angabe:Jong-Whi Park and Şevin Turcan
E-Jahr:2019
Jahr:22 October 2019
Umfang:17 S.
Fussnoten:Gesehen am 20.12.2019
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2019
Band/Heft Quelle:11(2019,10) Artikel-Nummer 1616, 17 Seiten
ISSN Quelle:2072-6694
Abstract:Targeting the epigenome has been considered a compelling treatment modality for several cancers, including gliomas. Nearly 80% of the lower-grade gliomas and secondary glioblastomas harbor recurrent mutations in isocitrate dehydrogenase (IDH). Mutant IDH generates high levels of 2-hydroxyglutarate (2-HG) that inhibit various components of the epigenetic machinery, including histone and DNA demethylases. The encouraging results from current epigenetic therapies in hematological malignancies have reinvigorated the interest in solid tumors and gliomas, both preclinically and clinically. Here, we summarize the recent advancements in epigenetic therapy for lower-grade gliomas and discuss the challenges associated with current treatment options. A particular focus is placed on therapeutic mechanisms underlying favorable outcome with epigenetic-based drugs in basic and translational research of gliomas. This review also highlights emerging bridges to combination treatment with respect to epigenetic drugs. Given that epigenetic therapies, particularly DNA methylation inhibitors, increase tumor immunogenicity and antitumor immune responses, appropriate drug combinations with immune checkpoint inhibitors may lead to improvement of treatment effectiveness of immunotherapy, ultimately leading to tumor cell eradication.
DOI:doi:10.3390/cancers11101616
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.3390/cancers11101616
 Verlag: https://www.mdpi.com/2072-6694/11/10/1616
 DOI: https://doi.org/10.3390/cancers11101616
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:<i>IDH</i>-mutant gliomas
 epigenetic therapies
 lower-grade gliomas
K10plus-PPN:168614895X
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68470219   QR-Code
zum Seitenanfang